GBGiovanni Bolcato

Giovanni Bolcato

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Giovanni Bolcato has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Towards Multitargeted Ligands as Pain Therapeutics: Dual Ligands of the Cavα2δ‐1 Subunit of Voltage‐Gated Calcium Channel and the μ‐Opioid Receptor

    by Anita Wegert, Menno Monnee, Wouter de Graaf, Frank van Holst, Giovanni Bolcato, José Luis Díaz, Albert Dordal, Enrique Portillo‐Salido, Raquel F. Reinoso, Sandra Yeste, et al.

    The synthesis and pharmacological activity of a new series of dual ligands combining activities towards the α2δ‐1 subunit of voltage‐gated calcium channels (Cavα2δ‐1) and the μ‐opioid receptor (MOR) as novel pain therapeutics are reported. A careful exploration of the pharmacophores related to both targets, which in principle had few common characteristics, led to the design of novel compounds exhibiting both activities. The construction of the dual ligands started from published Cavα2δ‐1 ligands, onto which MOR ligand pharmacophoric elements were added. This exercise led to new amino‐acidic substances with good affinities on both targets as well as good metabolic and physicochemical profiles and low potential for drug‐drug interactions. A representative compound, (2S,4S)‐4‐(4‐chloro‐3‐(((cis)‐4‐(dimethylamino)‐4‐phenylcyclohexyl)methyl)‐5‐fluorophenoxy)pyrrolidine‐2‐carboxylic acid, displayed promising analgesic activities in several in vivo pain models as well as a reduced side‐effect profile in relation to morphine.


  • [1,2,4]Triazolo[1,5‐c]pyrimidines as Tools to Investigate A3 Adenosine Receptors in Cancer Cell Lines

    by Stephanie Federico, Margherita Persico, Letizia Trevisan, Chiara Biasinutto, Giovanni Bolcato, Veronica Salmaso, Tatiana Da Ros, Teresa Gianferrara, Filippo Prencipe, Sonja Kachler, et al.

    The A3 adenosine receptor is an interesting target whose role in cancer is controversial. In this work, a structural investigation at the 2‐position of the [1,2,4]triazolo[1,5‐c]pyrimidine nucleus was performed, finding new potent and selective A3 adenosine receptor antagonists such as the ethyl 2‐(4‐methoxyphenyl)‐5‐(methylamino)‐[1,2,4]triazolo[1,5‐c]pyrimidine‐8‐carboxylate (20, DZ123) that showed a Ki value of 0.47 nM and an exceptional selectivity profile over the other adenosine receptor subtypes. Computational studies were performed to rationalize the affinity and the selectivity profile of the tested compounds at the A3 adenosine receptor and the A1 and A2A adenosine receptors. Compound 20 was tested on both A3 adenosine receptor positive cell lines (CHO‐A3AR transfected, THP1 and HCT16) and on A3 negative cancer cell lines, showing no effect in the latter and a pro‐proliferative effect at a low concentration in the former. These interesting results pave the way to further investigation on both the mechanism involved and potential therapeutic applications.


  • Front Cover: Are Two Riboses Better Than One? The Case of the Recognition and Activation of Adenosine Receptors (ChemMedChem 14/2023)

    by Teresa Gianferrara, Matteo Pavan, Davide Bassani, Fabrizio Vincenzi, Silvia Pasquini, Giovanni Bolcato, Katia Varani, Giampiero Spalluto, Stephanie Federico, Stefano Moro

  • Open Access

    Are Two Riboses Better Than One? The Case of the Recognition and Activation of Adenosine Receptors

    by Teresa Gianferrara, Matteo Pavan, Davide Bassani, Fabrizio Vincenzi, Silvia Pasquini, Giovanni Bolcato, Katia Varani, Giampiero Spalluto, Stephanie Federico, Stefano Moro

    Traditionally, molecular recognition between the orthosteric site of adenosine receptors and their endogenous ligand occurs with a 1 : 1 stoichiometry. Inspired by previous mechanistic insights derived from supervised molecular dynamics (SuMD) simulations, which suggested an alternative 2 : 1 binding stoichiometry, we synthesized BRA1, a bis‐ribosyl adenosine derivative, tested its ability to bind to and activate members of the adenosine receptor family, and rationalized its activity through molecular modeling.